Clinical Features, Tests, and Causes of Growth Hormone Deficiency

MacGillivray, Margaret H.

doi:10.1007/978-1-4615-7201-5_5

Cited by 4 publications

(2 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This observation is in accordance with previous investigations that report that most GH release occurs usually in the first 90-120 min of physiological sleep [MacGillivray, 1986;Martin, 19861. No correlation was found between nocturnal GH concentration and age ( r = -.16; P > .50), height ( r = .27; .20 < P < .50), bone age ( r = -.18; P > .50), L-dopa peak ( r = .20; P > .50), Tanner staging ( r = -.lo; P > .50), or maximum nocturnal peak and L-dopa peak ( r = .27; .20 < P < 50). A similar observation had been reported in a previous study of children with delayed growth [Costin and Kaufmann, 19871.…”

Section: Resultssupporting

confidence: 93%

Nocturnal rhythm of growth hormone in Duchenne patients: Effect of different doses of mazindol and/or cyproheptadine

et al. 1989

View full text Add to dashboard Cite

Human growth hormone (hGH) inhibition may be beneficial for Duchenne muscular dystrophy (DMD) patients and slow the rate of progression of the disease. The purpose of the present investigation was 1) to assess, before any therapeutic trial, the natural growth hormone (GH) rhythm during physiological sleep in DMD patients and in normal control boys of comparable age; 2) to evaluate the effect of different doses of two potential GH inhibitors on nocturnal GH secretion in DMD patients receiving mazindol (1-4 mg), cyproheptadine (4-8 mg), or both drugs. The results from the present investigation showed 1) wide variability in nocturnal GH secretion before medication; 2) no correlation between nocturnal GH concentration and height, age, bone age, L-dopa provocative test, or Tanner staging; and 3) no consistent effect on GH release after mazindol, cyproheptadine therapy, or combined therapy.

show abstract

Section: Resultssupporting

confidence: 93%

Nocturnal rhythm of growth hormone in Duchenne patients: Effect of different doses of mazindol and/or cyproheptadine

et al. 1989

View full text Add to dashboard Cite

show abstract

“…According to Underwood and Van Wyk [1985] and MacGillivray [1986] -70-75% of normal children respond to Ldopa. The definition of "normal" is still arbitrary, since sorne authors consider a normal response to L-dopa a peak above 7 ng/ml, others a peak above 9 or 10 ng/ml [MacGillivray, 1986;Costin and Kaufman, 19871. In any case, the results from the present investigation suggest an apparently normal response of GH release after Ldopa in nonrnedicated DMD patients.…”

Section: Response To L-dopa Before Mazindolmentioning

confidence: 99%

Effect of mazindol on growth hormone levels in patients with Duchenne muscular dystrophy

et al. 1988

View full text Add to dashboard Cite

Human growth hormone (HGH) inhibition may be beneficial in Duchenne muscular dystrophy (DMD) and slow down the rate of progression of the disease. The purposes of the present investigation were: 1) to assess, through pharmacological stimuli (L-dopa test), the HGH response in untreated DMD patients, and 2) to evaluate the inhibitory effect of mazindol on HGH levels as a potential treatment for DMD. In 55 DMD patients, HGH levels were measured through the L-dopa test, and 40 received mazindol. After 1 year, there was wide variability in the individual response to mazindol. An apparent diminution in the mean HGH level was observed in the whole group of patients; this was statistically significant after 3 and 6 months but not after 9 and 12 months of treatment. The results suggest that this drug is not effective for arresting growth or inhibiting HGH secretion for a prolonged period of time.

show abstract

The relationship of rat brain weight and pituitary weight to postnatal growth after prenatal exposure to methylazoxymethanol

Rodier

Kates

White

et al. 1991

Neurotoxicology and Teratology

View full text Add to dashboard Cite

Clinical Features, Tests, and Causes of Growth Hormone Deficiency

Cited by 4 publications

References 64 publications

Nocturnal rhythm of growth hormone in Duchenne patients: Effect of different doses of mazindol and/or cyproheptadine

Nocturnal rhythm of growth hormone in Duchenne patients: Effect of different doses of mazindol and/or cyproheptadine

Effect of mazindol on growth hormone levels in patients with Duchenne muscular dystrophy

The relationship of rat brain weight and pituitary weight to postnatal growth after prenatal exposure to methylazoxymethanol

Contact Info

Product

Resources

About